Editas Medicine is a clinical-stage biotechnology company developing genome editing treatments using CRISPR technology. The company's pipeline includes EDIT-401, a one-time therapy aimed at lowering cholesterol levels in hyperlipidemia patients, as well as investigational medicines for sickle cell disease and transfusion-dependent beta thalassemia. It also pursues in vivo gene editing approaches for various tissues and collaborates with Juno Therapeutics on experimental T-cell therapies targeting cancers and autoimmune disorders.

entry readiness 48 · WEAK SETUP · exit proximity 0

Value area 2.52–3.19 · 98% of 120d volume overhead · heavy supply